{
  "docId": "019de076-f497-7249-9bc1-6e417e62b814",
  "docSlug": "fb4563ff56b082126dc8200b1dba24d8",
  "documentTitle": "BenevolentAI | Results Presentation Deck | 23 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 23,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f497-7249-9bc1-6e417e62b814/7",
  "deckHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814",
  "deckJsonHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814.json",
  "deckAnchorHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f3b8c95-fa25-45e2-ae84-c7e4c7896bd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.81,
        "y": 0.55
      },
      "kind": "list",
      "text": "Joerg Moeller appointed as CEO in January 2024; Catherine Isted appointed as CFO and Christina Busmalis appointed as Chief Revenue Officer; Strategic review led to cash runway extension to at least mid-2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ac54043-80cc-4649-852f-18df54518105",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.24,
        "y": 0.55
      },
      "kind": "list",
      "text": "BEN-8744 for ulcerative colitis entered Phase Ia in August 2023, with topline data readout expected late Q1 2024; BEN-28010 for GBM completed IND-enabling studies; BEN-2293 for AD, no further investment as announced in May",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27c5821a-abe6-4d9e-92d9-e4c3b6fe8679",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "New Strategic Collaboration signed with Merck KGaA to deliver novel drug candidates, agreement worth up to $594m; Progress being made towards target selection in Heart Failure and SLE from AstraZeneca collaboration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38c80363-0c6e-41ec-9df7-e7136666fa5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.62,
        "y": 0.55
      },
      "kind": "list",
      "text": "Further enhancement and investment in the platform in key areas; Expansion of capabilities, offerings and prediction methodology within the platform; Enhancements assist both collaboration partners as well as own internal pipeline programmes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4c1b191-f605-4d01-aa9a-b029c77a4202",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.43,
        "y": 0.55
      },
      "kind": "list",
      "text": "Initial product development substantially completed alongside user testing; Market assessment underway with results expected in early Q2 2024 which will determine strategic priority",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb8918a5-3125-4022-bb49-3d2638bcd317",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "2023 Operational and Corporate Highlights (including post period)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed21ec21-2bbb-4364-8e37-804b15d96b6e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "7d86d8f9-eac8-46e8-a162-764a0d279492",
      "evidence": "list/bullet: Further enhancement and investment in the platform in key areas...",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 5,
      "beatId": "de08d32a-7c0e-40f4-9aaf-8f3a0f4da506",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "Overview of the Benevolent Platform™ and its revenue streams",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b0e19ace-ba0d-475a-81b8-bb29008de35f",
      "evidence": "The deck's overall narrative and key takeaways",
      "position": 1,
      "objective": "Communicating the why, how, and what of BenevolentAI's AI-driven drug discovery",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}